Business Wire

Ultivue to Participate in the Stifel 2021 Virtual Healthcare Conference

Share

Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, will participate in the Stifel 2021 Virtual Healthcare Conference to be held November 15th – 17, 2021. The conference incorporates presentations and innovative panel discussions hosted by senior leadership in the health care industry.

Ultivue’s President and Chief Executive Officer, Jacques Corriveau, and Chief Financial Offer, Richard C. Malabre, will present at 9:20 am ET on November 17. Interested parties may listen to the presentation using the following link: Ultivue Stifel Presentation

“We look forward to meeting investors and sharing our vision for continued rapid growth and exciting new products. Ultivue is at the forefront of innovation for tissue-based assays providing critical insights to researchers and pathologists from precious samples” said Jacques Corriveau, President and CEO.

About Ultivue

Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.

About Stifel

Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities.

Stifel hosts several client conferences and events each year, attracting top institutional investors as well as leading companies in their sectors of focus.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Richard C. Malabre
Chief Financial Officer
+1 617.710.1341
Richard.Malabre@Ultivue.com

Adrian Arechiga Ph.D.
VP Marketing
+49 176 3039 0757
Adrian.Arechiga@Ultivue.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DEXLEVO's Liquid Polymer Filler Raises KRW 26 Billion in Pre-IPO Funding3.12.2021 10:41:00 EET | Press release

DEXLEVO has completed its pre-IPO funding of KRW 26 billion. It thus increased its valuation by six times compared to the Series B funding in 2018 thanks to its commercialization performance such as obtaining the European Union’s CE certification on the liquid polymer filler (product name: GOURI) in May of this year. The company plans to build a new cGMP-grade (current Good Manufacturing Practice) production facility in Songdo with the proceeds raised this time and start marketing its flagship product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202006086/en/ DEXLEVO's GOURI, the world's 1st Fully Liquid type PCL Injectable. (Graphic: Business Wire) According to industry sources on November 25, DEXLEVO has completed a total of KRW 26 billion in pre-IPO funding from existing investors such as Magna Investment, Smilegate Investment, Hyundai Venture Investment Corp., and Shinhan Capital. Magna Investment and Smilegate Inv

Seoul Viosys Provides Air Purifier Sterilizers, Which Dramatically Reduce the Risk of COVID-19 Infection, to 300 Small Businesses in Korea for Free3.12.2021 08:59:00 EET | Press release

While Living with COVID-19 campaign has kicked off in earnest, Seoul Viosys Co., Ltd. (KOSDAQ: 092190), a company specializing in optical semiconductors, provided Violeds Air Purifying Sterilizers that can reduce the indoor COVID-19 infection rate by 1/30 to 300 Korean facilities free of charge, with a good intention to support Korean small business owners. In addition, it announced that it would provide the Air Purifying Sterilizer license to the partners who can supply them worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202006063/en/ Air flow analysis while the air purifier sterilizer is running (Graphic: Business Wire) Seoul Viosys conducted an air sterilization experiment based on the study of the Korea Central Disease Control Headquarters and the Korea Institute of Science and Technology (KIST), which found out that opening windows frequently can lower the infection rate. When compared to opening windows a

BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease3.12.2021 07:00:00 EET | Press release

BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT® (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). This disease is a rare, life-threatening, and debilitating condition of the lymph nodes and related tissues. Siltuximab is a monoclonal antibody approved in the United States, European Union, and other countries and regions around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202006056/en/ “Today’s approval provides a new treatment for patients in China with this rare systemic disorder,” commented Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China at BeiGene. “This approval is our

Bluehole Publishes a Feature Story on China’s Recent Vaping Regulations3.12.2021 06:04:00 EET | Press release

China’s leading vaping media, Bluehole New Consumption, today published a feature story on recent vaping regulation updates in China. Here below is the full article in English: On December 2, 2021, China’s State Tobacco Monopoly Administration issued the draft rules governing e-cigarettes while the regulator has just released the exposure draft of national standards of e-cigarettes on November 30, 2021. Previously, China announced to bring e-cigarettes under tobacco monopoly law on November 26, hence the legal status of e-cigarettes. The recent regulation updates have eliminated the uncertainties about the future of Chinese vaping industry, paving the way for the industry’s sustainable development. According to iiMedia Research Group, the size of Chinese’ e-cigarette market has grown from RMB 550 million (USD 86 million) in 2013 to RMB 8.38 billion (USD 1.31 billion) in 2020, witnessing an eight-year compound annual growth rate of 72.5%. World Health Organization estimates that China h

ST Energy Transition I Ltd. Announces Pricing of $250 Million Initial Public Offering3.12.2021 05:34:00 EET | Press release

ST Energy Transition I Ltd. (the “Company”) announced today the pricing of 25,000,000 Stakeholder Aligned Initial Listing, or SAILSM security, at a price of $10.00 per SAILSM security. The SAILSM securities will be listed on the New York Stock Exchange and trade under the ticker symbol “STET.U” beginning December 3, 2021. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination with a target in any industry or geographic location, it intends to focus its search on opportunities that contribute in positive ways towards energy transition and clean energy technology. The Company’s board is led by John Fredriksen, chairperson, and includes independent directors Ole-Eirik Lerøy, Cato Stonex, James O’Shaughnessy, Tore Myrholt and Annika Sigfrid. Gunnar Eliassen is the Chief Executive Offi

Bentley Systems Announces Winners of the 2021 Going Digital Awards in Infrastructure3.12.2021 00:01:00 EET | Press release

Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, today announced the winners of the 2021 Going Digital Awards in Infrastructure. The annual awards program recognizes the extraordinary work of Bentley software users advancing infrastructure design, construction, and operations throughout the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005219/en/ Bentley Systems Announces Winners of the 2021 Going Digital Awards in Infrastructure (Photo: Business Wire) Sixteen independent jury panels selected the 57 finalists from nearly 300 nominations submitted by more than 230 organizations from 45 countries encompassing 19 categories. To see the Going Digital Awards in Infrastructure finalists present their projects, click here. Bentley Systems showcased 19 Going Digital Awards in Infrastructure winners on December 2 during the 2021 Year in Infrastructure and Going Digital Awards

Vifor Pharma comments on market speculations2.12.2021 20:40:00 EET | Press release

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Due to current market speculations, Vifor Pharma Group states the following: Vifor Pharma Group systematically reviews options that can strengthen its market position and/or accelerate the growth of the company both organically and through partnerships and acquisitions. Vifor Pharma is therefore regularly in discussions with other market participants and does not comment on them. About Vifor Pharma Group Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom